Capsugel: Micro-Dosing Tech Can Cut Drug Development by 6 Months

By Dan Stanton

- Last updated on GMT

Related tags: New york city, Pharmacology, Clinical trial

Capsugel says its Xcelodose Precision Powder Micro-Dosing System can shorten drug development time by up to six months. spoke with Missy Lowery, Marketing Manager for the Americas at Capsugel, at this year’s Interphex in New York City about the company’s Fast track Solutions System and its Xcelodose proprietary technology.

“Speed to market is the most important”​ thing in the pharma market today, she told us.

“Capsugel’s proprietary technology provides an RSD of 1% for quantities as low as 100microgrammes directly into the capsule.”

She told us that Xcelodose was established in order for companies to put APIs directly in a capsule without going through the process of formulation first.

From concept to first clinical trial, Lowery said this technology has sped the whole process up by more than six months.

With “the accuracy of dosing, the continuation of the RSD,”​ she added, “there is nothing like it on the market right now.”

Related news

Show more

Related products

show more

Strategies to Select and Deliver the Right Candidate

Strategies to Select and Deliver the Right Candidate

Catalent Pharma Solutions | 05-Mar-2018 | Technical / White Paper

Does your candidate have what it takes to succeed? Do you have the information needed to make the right decisions about your candidate’s path to the clinic?...

Roquette Oral Dose Case Study - Part IV

Roquette Oral Dose Case Study - Part IV

Roquette Pharma Solutions | 04-Dec-2017 | Case Study

Download the latest Roquette case study and learn more on how PEARLITOL® Flash mannitol and starch compound offers inert stability, fast disintegration...

Related suppliers

Follow us

Featured Events

View more


View more